Tclin PSMB8 Proteasome subunit beta type-8

Protein Summary

Description

The proteasome is a multicatalytic proteinase complex which is characterized by its ability to cleave peptides with Arg, Phe, Tyr, Leu, and Glu adjacent to the leaving group at neutral or slightly basic pH. The proteasome has an ATP-dependent proteolytic activity. This subunit is involved in antigen processing to generate class I binding peptides. Replacement of PSMB5 by PSMB8 increases the capacity of the immunoproteasome to cleave model peptides after hydrophobic and basic residues. Acts as a major component of interferon gamma-induced sensitivity. Plays a key role in apoptosis via the degradation of the apoptotic inhibitor MCL1. May be involved in the inflammatory response pathway. In cancer cells, substitution of isoform 1 (E2) by isoform 2 (E1) results in immunoproteasome deficiency. Required for the differentiation of preadipocytes into adipocytes. The proteasome is a multicatalytic proteinase complex with a highly ordered ring-shaped 20S core structure. The core structure is composed of 4 rings of 28 non-identical subunits; 2 rings are composed of 7 alpha subunits and 2 rings are composed of 7 beta subunits. Proteasomes are distributed throughout eukaryotic cells at a high concentration and cleave peptides in an ATP/ubiquitin-dependent process in a non-lysosomal pathway. An essential function of a modified proteasome, the immunoproteasome, is the processing of class I MHC peptides. This gene encodes a member of the proteasome B-type family, also known as the T1B family, that is a 20S core beta subunit. This gene is located in the class II region of the MHC (major histocompatibility complex). Expression of this gene is induced by gamma interferon and this gene product replaces catalytic subunit 3 (proteasome beta 5 subunit) in the immunoproteasome. Proteolytic processing is required to generate a mature subunit. Two alternative transcripts encoding two isoforms have been identified; both isoforms are processed to yield the same mature subunit. [provided by RefSeq, Jul 2008]

Uniprot Accession IDs

• P28062
• B0UZC0
• Q29824
• Q5JNW6
• Q5QNR8
• Q96J48

Gene Name

• PSMB8

Ensembl ID

• ENST00000374881
• ENSP00000364015
• ENSG00000204264
• ENST00000374882
• ENSP00000364016
• ENST00000383236
• ENSP00000372723
• ENSG00000206298
• ENST00000383238
• ENSP00000372725
• ENST00000416134
• ENSP00000397057
• ENSG00000235715
• ENST00000416564
• ENSP00000408825
• ENSG00000226201
• ENST00000421445
• ENSP00000402406
• ENSG00000236443
• ENST00000429645
• ENSP00000394155
• ENST00000435978
• ENSP00000414731
• ENSG00000231631
• ENST00000436627
• ENSP00000392693
• ENSG00000230669
• ENST00000438442
• ENSP00000404585
• ENST00000441960
• ENSP00000407539
• ENSG00000230034
• ENST00000452573
• ENSP00000412618
• ENST00000455660
• ENSP00000406797
• ENST00000457261
• ENSP00000414770

Symbol

• LMP7
• PSMB5i
• RING10
• Y2
• JMP
• ALDD
• LMP7
• NKJO
• D6S216
• PRAAS1
• PSMB5i
• RING10
• D6S216E

Knowledge Table

Most Knowledge About	Knowledge Value (0 to 1 scale)
biological process	0.98
PubMedID	0.97
gene perturbation	0.96
transcription factor perturbation	0.91
virus perturbation	0.76

Protein Classes

No PANTHER Classes or DTO Classes found

IDG Development Level Summary

Tdark

These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 534.67   (req: < 5)

Gene RIFs: 77   (req: <= 3)

Antibodies: 374   (req: <= 50)

Tbio

These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:

Pubmed score: 534.67   (req: >= 5)

Gene RIFs: 77   (req: > 3)

Antibodies: 374   (req: > 50)

- OR - satisfy the following criterion:

Gene Ontology Terms: 12

Tchem

Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions

Active Ligands: 181

Tclin

Target has at least one approved drug - AND - satisfies the preceding conditions

Active Drug: 1